NTC
IOVA icon

NF Trinity Capital’s Iovance Biotherapeutics IOVA Stock Holding History

NF Trinity Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$2.17M Hold
228,442
– – 0.35% 36
2018
Q4 		$2.02M Buy
228,442
+103,588
+83% +$999K 0.33% 39
2018
Q3 		$1.41M Hold
124,854
– – 0.19% 49
2018
Q2 		$1.6M Buy
+124,854
New +$1.82M 0.22% 53

Other funds holding IOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NF Trinity Capital's IOVA Position: Q1 2019 in Review

NF Trinity Capital held its Iovance Biotherapeutics (IOVA) position steady in Q1 2019 at 228,442 shares worth $2.17M. The position accounts for 0.35% of the portfolio, ranked #36.

NF Trinity Capital first reported a position in IOVA in Q2 2018 and has held it in 4 quarters since. 153 funds tracked by Wall St. Rank hold IOVA as of Q1 2019.

  • NF Trinity Capital held 228,442 shares of Iovance Biotherapeutics worth $2.17M as of Q1 2019.
  • NF Trinity Capital left its Iovance Biotherapeutics share count unchanged in Q1 2019.
  • Iovance Biotherapeutics made up 0.35% of NF Trinity Capital's portfolio in Q1 2019, its #36 holding.
  • NF Trinity Capital first reported a position in Iovance Biotherapeutics in Q2 2018 and has held it in 4 quarters since.
  • 153 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2019.

Based on NF Trinity Capital's 13F filing for Q1 2019, filed 10 May 2019.